



(11) **EP 1 648 509 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 39/395 (2006.01) **C07K 16/22** (2006.01)
G01N 33/53 (2006.01) **C12N 15/68** (2006.01)
C12N 5/10 (2006.01) **A61P 25/00** (2006.01)
A61P 35/00 (2006.01)

(48) Corrigendum issued on:
24.10.2012 Bulletin 2012/43

(86) International application number:
PCT/US2004/022876

(45) Date of publication and mention
of the grant of the patent:
12.09.2012 Bulletin 2012/37

(87) International publication number:
WO 2005/019266 (03.03.2005 Gazette 2005/09)

(21) Application number: **04778409.5**

(22) Date of filing: **15.07.2004**

(54) **HUMAN ANTI-NGF NEUTRALIZING ANTIBODIES AS SELECTIVE NGF PATHWAY INHIBITORS**
HUMANE ANTI-NGF NEUTRALISIERENDE ANTIKÖRPER ALS SELEKTIVE NGF-HEMMER
ANTICORPS NEUTRALISANTS ANTI-NGF HUMAINS UTILISES COMME INHIBITEURS SELECTIFS
DE LA VOIE DE NGF

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL HR LT LV MK

- **HUANG, Haichun**
Fremont, CA 94539 (US)
- **INOUE, Heather**
Oak Park, CA 91377 (US)
- **ZHANG, Tie, J.**
Thousand Oaks, CA 91320 (US)
- **MARTIN, Frank**
Newbury Park, CA 91320 (US)

(30) Priority: **15.07.2003 US 487431 P**

(43) Date of publication of application:
26.04.2006 Bulletin 2006/17

(74) Representative: **Grünecker, Kinkeldey,**
Stockmair & Schwanhäusser
Leopoldstrasse 4
80802 München (DE)

(60) Divisional application:
10011652.4 / 2 364 728

(73) Proprietors:
• **Amgen Inc.**
Thousand Oaks, CA 91320-1799 (US)
• **Medarex, Inc.**
Princeton, NJ 08543 (US)

(56) References cited:
WO-A-01/78698 WO-A-02/096458
US-A1- 2001 046 959

(72) Inventors:
• **WILD, Kenneth, D., Jr.**
Simi Valley, CA 93065 (US)
• **TREANOR, James, J., S.**
Sherman Oaks, CA 91423 (US)

- **HOLT L J ET AL: "Domain antibodies: proteins for therapy" TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 11, November 2003 (2003-11), pages 484-490, XP004467495 ISSN: 0167-7799**

EP 1 648 509 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).